Past President, American Association of Pharmaceutical Scientists

Andy has 28 years of experience working within the biotechnology and pharmaceutical industry on both the innovator and supplier sides in the fields of toxicology, nonclinical and clinical pharmacology, and drug disposition.  Andy has served in executive roles with Attralus Therapeutics, Charles River Laboratories, WIL Research Laboratories (acquired by CRL), Seventh Wave Laboratories (now Inotiv), as well as served in key scientific roles at Eli Lilly and Biogen. He has had operational and financial accountability for budgets of >$700M.  Andy has served on several scientific advisory Boards, various non-profit Boards, and provided expert advice for >30 pharmaceutical companies.  He earned his BS in Zoology and PhD in Pharmaceutical Chemistry from The Ohio State University.  He has continued his support of the University through service on the Dean’s Corporate Council for the College of Pharmacy, and he serves the Division of Pharmaceutical Chemistry as an Adjunct Professor.